Lundbeck appoints new vice president of global pricing and market access
11 January 2013 | By H. Lundbeck A/S
The move strengthens the company's capacity to bring drugs to market effectively...
List view / Grid view
11 January 2013 | By H. Lundbeck A/S
The move strengthens the company's capacity to bring drugs to market effectively...
11 January 2013 | By Novartis
Data published today...
10 January 2013 | By Sirius Analytical Instruments Ltd
Sirius Analytical Instruments Ltd announces the introduction of a new product...
10 January 2013 | By Catalent Pharma Solutions
The investment will focus on expanding pMDI clinical and commercial supply capabilities...
An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.1 Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced today CE Marking (Conformité…
9 January 2013 | By GlaxoSmithKline
GSK and Theravance announced the submission of a regulatory application...
9 January 2013 | By B&W Tek, Inc.
B&W Tek, Inc., announces Dr. Katherine Bakeev as the new Director of Analytical Services and Support...
8 January 2013 | By Daiichi Sankyo
Daiichi Sankyo & Amplimmune have entered into a broad strategic collaboration...
8 January 2013 | By Sanofi
Sanofi will provide an update on its Research & Development (R&D) pipeline...
8 January 2013 | By Abbott
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States...
Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.
8 January 2013 | By FOSS NIRSystems Inc
FOSS NIRSystems, Inc. announce that a new FOSS NIR article has been published...
7 January 2013 | By Gilead Sciences
Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection...
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
7 January 2013 | By Sirius Analytical Instruments Ltd
“We are delighted to begin this strategic partnership with Paraytec..."